Japan Drug Delivery Devices Market Outlook 2031:
The Japan drug delivery devices market size was valued at USD 3.25 Billion in 2022 and is projected to reach USD 4.91 Billion by 2031, expanding at a CAGR of 4.7% during the forecast period 2023 - 2031. The growth of the market is attributed to decrease the chances of side effects by optimizing the drug presence at the target site. It helps in reducing the dose and associated side effects along with decreasing the product price by reducing the amount of active pharmaceutical ingredients.
Drug delivery devices are specialized tools helps to deliver drugs through various route of administration. These devices are used for treatments of various diseases. These devices can be implantable or conventional. Drug delivery devices have different features including specific therapeutic effect, high degree of safety, target specificity, dose optimization, and efficiency. Drug delivery devices control the location and rate of drug released in the body.
The medications are taken in different ways such as by absorption, through the skin, by swallowing, by inhalation, and by intravenous injection. For this, drug delivery devices are used to deliver drugs in the specific device type. The drug delivery devices have changed drastically in past few decades and even greater changes are projected in the near future. Growing geriatric population in Japan and increasing adoption of biologics is expected to boost the market growth.
Japan Drug Delivery Devices Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of chronic diseases is anticipated to spur the market expansion during the forecast period.
- Rapid growth of healthcare sector is major factor driving the market growth.
- Strict government rules and regulations regarding drug delivery devices are estimated to hinder the market expansion during the forecast period.
- Inefficiency in delivering poorly soluble drugs act as main challenge that can impede the market growth.
- R&D investment and technological advancement in drug delivery devices are expected to offer immense opportunities for the market players.
Scope of the Japan Drug Delivery Devices Market Report
The report on the Japan drug delivery devices market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Japan Drug Delivery Devices Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023-2031
|
|
Segmentation
|
Route of Administrations (Ocular, Topical, Injectable, Oral, and Others), Applications (Cardiovascular, Infectious Diseases, Cancer, Diabetes, and Others), End-users (Hospitals, Ambulatory Surgical Centers, and Others)
|
|
Country
|
Japan
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
GlaxoSmithKline Plc.; ANTARES PHARMA, Inc.; Novartis AG; Mylan N.V.; and Tasei Kako Co. Ltd.
|
Japan Drug Delivery Devices Market Segment Insights:
Oral segment is projected to account for a large market share
Based on route of administrations, the Japan drug delivery devices market is divided into ocular, topical, injectable, oral, and others. The oral segment is expected to constitute a key share of the market during the forecast period owing to highly preferable route of administration, easy to use, and drug stability.
The oral drug delivery system involves various ranges of dosage forms such as capsules, solutions, tablets, syrups, and suspensions. However, the injectable segment is anticipated to expand at a rapid pace during the forecast period due to technological advancement in injectable drug delivery system such as introduction of pen injectors and prefilled syringes.
Cancer segment is projected to hold a key market share
On the basis of applications, the market is segmented into cardiovascular, infectious diseases, cancer, diabetes, and others. The cancer segment is expected to represent a key share of the market in the coming years due to increasing prevalence of cancer and government’s initiatives to spread awareness about cancer and its treatments.
On the other hand, the diabetes segment is anticipated to expand at a rapid pace during the forecast period owing to rising number of diagnosed diabetes cases.
Hospitals segment is projected to constitute a major market share
In terms of end-users, the Japan drug delivery devices market is segregated into hospitals, ambulatory surgical centers, and others. The hospitals segment is expected to account for a key share of the market during the forecast period owing to growing cases of neurological disorders, diabetes, and cancer that requires various types of drugs for treatment.
However, the ambulatory surgical centers segment is anticipated to expand at a rapid pace during the forecast period due to increasing focus on adopting and developing drug delivery devices.
Segments
The Japan drug delivery devices market has been segmented on the basis of
Route of Administrations
- Ocular
- Topical
- Injectable
- Oral
- Others
Applications
- Cardiovascular
- Infectious Diseases
- Cancer
- Diabetes
- Others
End-users
- Hospitals
- Ambulatory Surgical Centers
- Others
Country
Key Players
Competitive Landscape
Key players competing in the Japan drug delivery devices market include GlaxoSmithKline Plc.; ANTARES PHARMA, Inc.; Novartis AG; Mylan N.V.; and Tasei Kako Co. Ltd. Some of these players are engaged in several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
